BACKGROUND: Oral liquid solutions of the diuretic active ingredient furosemide (FUR) marketed across Europe do not comply with recent requirements for paediatric preparation owing to their ethanol content and, moreover, in some countries only tablet or injection dosage forms of furosemide are available. OBJECTIVES: To formulate extemporaneous paediatric ethanol-free solutions of FUR (2 mg/mL) with suitable solubility in the aqueous vehicle and an acceptable taste and to evaluate their stability under two different storage conditions during a 9-month study period. METHODS: Our work presents two developed formulations of FUR ethanol-free paediatric oral solutions 2 mg/mL for easy extemporaneous compounding in a pharmacy. FUR solubility avoiding the use of ethanol was achieved using sodium hydroxide (formulation F1) or disodium hydrogen phosphate dodecahydrate (formulation F2). The preparations were stored at 25°C±3°C or at 40°C±0.5°C and protected from light. For FUR and preservative, methylparaben (MP), a stability assay was conducted by a high-performance liquid chromatography validated method and determination of pH stability. RESULTS: The remaining FUR concentration was >90% of the initial concentration after 270 days in both formulations at both storage conditions, 25°C and 40°C. The concentration of MP decreased significantly in the formulation F2 stored at 40°C. CONCLUSIONS: Both formulations were stable when stored at room temperature for up to 9 months; formulation F1 was stable even at 40°C. MP used as an antimicrobial agent fully satisfied the recommended criteria for preservative efficacy in oral preparations according to the European Pharmacopoeia 9.0 (5.1.3).

Department of Analytical Chemistry Charles University Hradec Kralove Czech Republic

Department of Pharmaceutical Technology Charles University Hradec Kralove Czech Republic

Hospital Pharmacy University Hospital Motol Prague Czech Republic

See more in PubMed

Sweetman SC. Martindale: the complete drug Reference. 37th Edn: Pharmaceutical Press, Furosemide, 2011:1421–5.

Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol 2005;59:674–6. 10.1111/j.1365-2125.2005.02410.x PubMed DOI PMC

Standing JF, Tuleu C. Paediatric formulations--getting to the heart of the problem. Int J Pharm 2005;300:56–66. 10.1016/j.ijpharm.2005.05.006 PubMed DOI

Cram A, Breitkreutz J, Desset-Brèthes S, et al. . Challenges of developing palatable oral paediatric formulations. Int J Pharm 2009;365:1–3. 10.1016/j.ijpharm.2008.09.015 PubMed DOI

Frusol 20 mg/5 ml oral solution. https://www.medicines.org.uk/emc/medicine/16559 Ref Nr.6:https://www.fass.se/LIF/product?userType=2&nplId=19880429000038 (accessed 13 May 2017).

Impugan 10 mg/ml orala droppar lösning. https://docetp.mpa.se/LMF/Impugan_oral_drops,_solution_SmPC (accessed 13 May 2017).

Lasix® liquidum. https://www.medikamente-per-klick.de/images/ecommerce/04/66/04661307_2011-08_de_o.pdf (accessed 13 May 2017).

Drugs Com. Ethanol in liquid preparations intended for children. Pediatrics 1984;73:405–7 http://pediatrics.aappublications.org/content/pediatrics/73/3/405.full.pdf PubMed

Salunke S, Giacoia G, Tuleu C. The STEP (Safety and Toxicity of Excipients for Paediatrics) database. Part 1-A need assessment study. Int J Pharm 2012;435:101–11. 10.1016/j.ijpharm.2012.05.004 PubMed DOI

Salunke S, Brandys B, Giacoia G, et al. . The STEP (Safety and Toxicity of Excipients for Paediatrics) database: part 2 - The pilot version. Int J Pharm 2013;457:310–22. 10.1016/j.ijpharm.2013.09.013 PubMed DOI

Fiocchi A, Riva E, Giovannini M. Ethanol in medicines and other products intended for children: commentary on a medical paradox. Nutr Res 1999;19:373–9. 10.1016/S0271-5317(99)00004-4 DOI

Draft guideline on pharmaceutical development of medicines for paediatric use. European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/06/WC500107908.pdf (accessed 13 May 2017).

EMA/ /HMPC/85114/2008. Reflection paper on ethanol content in herbal medicinal products and traditional herbal medicinal products used in children. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500070331.pdf (accessed 13 May 2017).

Troy DB, Remington: the science and practice of pharmacy. 21th Ed Philadelphia: Lippincott Williams, 2005. 1430.

EDQM. European Pharmacopoeia. 9th Edition, 2016.

ICH expert Working Group (2005) Validation of Analytical Procedures: text and Methodology Q2(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf (accessed 13 May 2017).

Ghanekar AG, Das Gupta V, Gibbs CW. Stability of furosemide in aqueous systems. J Pharm Sci 1978;67:808–11. 10.1002/jps.2600670621 PubMed DOI

Rowe RC. Handbook of Pharmaceutical Excipients. 6th Eds London: Pharmaceutical Press, 2009.

WHO Technical Report Series. Evaluation of Certain Food Additives and Contaminants 2007. http://apps.who.int/iris/bitstream/10665/43592/1/WHO_TRS_940_eng.pdf (accessed 13 May 2017). PubMed

Zahálka L, Matysová L, Šklubalová Z, et al. . Simultaneous determination of propranolol hydrochloride and sodium benzoate in oral liquid preparations by HPLC. Chromatographia 2013;76:1553–8. 10.1007/s10337-013-2457-z DOI

Klovrzová S, Zahálka L, Matysová L, et al. . Pediatric oral solutions with propranolol hydrochloride for extemporaneous compounding: the formulation and stability study. Ceska Slov Farm 2013;62:35–9. PubMed

Matysova L, Zahalkova O, Klovrzova S, et al. . Development of a gradient HPLC method for the simultaneous determination of sotalol and sorbate in oral liquid preparations using solid core stationary phase. J Anal Methods Chem 2015;2015:1–6. 10.1155/2015/806736 PubMed DOI PMC